Publications

• 1. Chang SL
  2. Seth P
  3. Zhu J
  4. Pendyala G
  5. Bidlack JM
  6. Kumar S
  The 27th Scientific Conference of the Society on NeuroImmune Pharmacology: New Delhi, India, March 15-18, 2023.; NeuroImmune pharmacology and therapeutics; Vol 2(2), pp. 187-244. 2023 Apr 10.
• 1. Kumar S
  2. Yelamanchili S
  3. Seth P
  4. Bidlack JM
  5. Pendyala G
  6. Maggirwar S
  7. Chang SL
  The Neuroimmune Pharmacology of SARS-CoV-2.; Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2021 Dec 22.
• 1. Bidlack JM
  2. Chang SL
  3. Fitting S
  4. Gendelman HE
  5. Gorantla S
  6. Kumar S
  7. Marcondes MCG
  8. Meigs DD
  9. Melendez LM
  10. Sariyer IK
  11. Yelamanchili S
  The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings.; Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2021 Nov 26.
• 1. Dorval L
  2. Knapp BI
  3. Majekodunmi OA
  4. Eliseeva S
  5. Bidlack JM
  Mice with high FGF21 serum levels had a reduced preference for morphine and an attenuated development of acute antinociceptive tolerance and physical dependence.; Neuropharmacology; Vol 202. 2021 Oct 26.
• 1. Kumar S
  2. Pendyala G
  3. Yelamanchili SV
  4. Seth P
  5. Maggirwar S
  6. Bidlack JM
  7. Chang SL
  Society on NeuroImmune Pharmacology COVID-19 Virtual Workshop.; Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2021 Jun 28.
• 1. Bartlett MJ
  2. Mabrouk OS
  3. Szabò L
  4. Flores AJ
  5. Parent KL
  6. Bidlack JM
  7. Heien ML
  8. Kennedy RT
  9. Polt R
  10. Sherman SJ
  11. Falk T
  The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia.; International journal of molecular sciences; Vol 22(1). 2020 Dec 22.
• 1. Barnett ME
  2. Knapp BI
  3. Bidlack JM
  Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through Gαz as Shown with Bioluminescence Resonance Energy Tranfer.; Molecular pharmacology; Vol 98(4). 2020 Oct.
• 1. Stevenson GW
  2. Giuvelis D
  3. Cormier J
  4. Cone K
  5. Atherton P
  6. Krivitsky R
  7. Warner E
  8. St Laurent B
  9. Dutra J
  10. Bidlack JM
  11. Szabò L
  12. Polt R
  13. Bilsky EJ
  Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration.; Psychopharmacology. 2020 Jan 07.
• 1. Stowell RD
  2. Sipe GO
  3. Dawes RP
  4. Batchelor HN
  5. Lordy KA
  6. Whitelaw BS
  7. Stoessel MB
  8. Bidlack JM
  9. Brown E
  10. Sur M
  11. Majewska AK
  Author Correction: Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex.; Nature neuroscience. 2019 Nov 27.
• 1. Stowell RD
  2. Sipe GO
  3. Dawes RP
  4. Batchelor HN
  5. Lordy KA
  6. Whitelaw BS
  7. Stoessel MB
  8. Bidlack JM
  9. Brown E
  10. Sur M
  11. Majewska AK
  Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex.; Nature neuroscience. 2019 Oct 21.
• 1. Bidlack JM
  2. Knapp BI
  3. Deaver DR
  4. Plotnikava M
  5. Arnelle D
  6. Wonsey AM
  7. Toh MF
  8. Pin SS
  9. Namchuk MN
  In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment for Major Depressive Disorder.; The Journal of pharmacology and experimental therapeutics. 2018 Aug 14.
• 1. Callaghan CK
  2. Rouine J
  3. Dean RL
  4. Knapp BI
  5. Bidlack JM
  6. Deaver DR
  7. O'Mara SM
  Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.; Brain, behavior, and immunity. 2017 Aug 24.
• 1. Lefever M
  2. Li Y
  3. Anglin B
  4. Muthu D
  5. Giuvelis D
  6. Lowery JJ
  7. Knapp BI
  8. Bidlack JM
  9. Bilsky EJ
  10. Polt R
  Structural Requirements for CNS Active Opioid Glycopeptides.; Journal of medicinal chemistry; Vol 58(15). 2015 Aug 13.
• 1. Li Y
  2. St Louis L
  3. Knapp BI
  4. Muthu D
  5. Anglin B
  6. Giuvelis D
  7. Bidlack JM
  8. Bilsky EJ
  9. Polt R
  Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin?; Journal of medicinal chemistry; Vol 57(6). 2014 Mar 27.
• 1. Sromek AW
  2. Provencher BA
  3. Russell S
  4. Chartoff E
  5. Knapp BI
  6. Bidlack JM
  7. Neumeyer JL
  Preliminary pharmacological evaluation of enantiomeric morphinans.; ACS chemical neuroscience; Vol 5(2). 2014 Feb 19.
• 1. Bidlack JM
  Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.; Advances in pharmacology (San Diego, Calif.); Vol 69. 2014.
• 1. Provencher BA
  2. Sromek AW
  3. Li W
  4. Russell S
  5. Chartoff E
  6. Knapp BI
  7. Bidlack JM
  8. Neumeyer JL
  Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.; Journal of medicinal chemistry; Vol 56(21). 2013 Nov 14.
• 1. Hoot MR
  2. Sypek EI
  3. Reilley KJ
  4. Carey AN
  5. Bidlack JM
  6. McLaughlin JP
  Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.; Behavioural pharmacology; Vol 24(2). 2013 Apr.
• 1. VanAlstine MA
  2. Wentland MP
  3. Alvarez J
  4. Cao Q
  5. Cohen DJ
  6. Knapp BI
  7. Bidlack JM
  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 23(7). 2013 Apr 1.
• 1. Wentland MP
  2. Jo S
  3. Gargano JM
  4. VanAlstine MA
  5. Cohen DJ
  6. Bidlack JM
  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC.; Bioorganic & medicinal chemistry letters; Vol 22(24). 2012 Dec 15.
• 1. Neumeyer JL
  2. Zhang B
  3. Zhang T
  4. Sromek AW
  5. Knapp BI
  6. Cohen DJ
  7. Bidlack JM
  Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.; Journal of medicinal chemistry; Vol 55(8). 2012 Apr 26.
• 1. Li Y
  2. Lefever MR
  3. Muthu D
  4. Bidlack JM
  5. Bilsky EJ
  6. Polt R
  Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.; Future medicinal chemistry; Vol 4(2). 2012 Feb.
• 1. Dean RL
  2. Eyerman D
  3. Todtenkopf MS
  4. Turncliff RZ
  5. Bidlack JM
  6. Deaver DR
  Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats.; Pharmacology, biochemistry, and behavior; Vol 100(3). 2012 Jan.
• 1. Yeomans L
  2. Muthu D
  3. Lowery JJ
  4. Martinez HN
  5. Abrell L
  6. Lin G
  7. Strom K
  8. Knapp BI
  9. Bidlack JM
  10. Bilsky EJ
  11. Polt R
  Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments.; Chemical biology & drug design; Vol 78(5). 2011 Nov.
• 1. Zhang B
  2. Zhang T
  3. Sromek AW
  4. Scrimale T
  5. Bidlack JM
  6. Neumeyer JL
  Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.; Bioorganic & medicinal chemistry; Vol 19(9). 2011 May 1.
• 1. Hough LB
  2. Nalwalk JW
  3. Yang J
  4. Conroy JL
  5. VanAlstine MA
  6. Yang W
  7. Gargano J
  8. Shan Z
  9. Zhang SZ
  10. Wentland MP
  11. Phillips JG
  12. Knapp BI
  13. Bidlack JM
  14. Zuiderveld OP
  15. Leurs R
  16. Ding X
  Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic.; Pain; Vol 152(4). 2011 Apr.
• 1. Zhang T
  2. Yan Z
  3. Sromek A
  4. Knapp BI
  5. Scrimale T
  6. Bidlack JM
  7. Neumeyer JL
  Aminothiazolomorphinans with mixed κ and μ opioid activity.; Journal of medicinal chemistry; Vol 54(6). 2011 Mar 24.
• 1. Lowery JJ
  2. Raymond TJ
  3. Giuvelis D
  4. Bidlack JM
  5. Polt R
  6. Bilsky EJ
  In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.; The Journal of pharmacology and experimental therapeutics; Vol 336(3). 2011 Mar.
• 1. Balboni G
  2. Salvadori S
  3. Marczak ED
  4. Knapp BI
  5. Bidlack JM
  6. Lazarus LH
  7. Peng X
  8. Si YG
  9. Neumeyer JL
  Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic.; European journal of medicinal chemistry; Vol 46(2). 2011 Feb.
• 1. Conroy JL
  2. Fang C
  3. Gu J
  4. Zeitlin SO
  5. Yang W
  6. Yang J
  7. VanAlstine MA
  8. Nalwalk JW
  9. Albrecht PJ
  10. Mazurkiewicz JE
  11. Snyder-Keller A
  12. Shan Z
  13. Zhang SZ
  14. Wentland MP
  15. Behr M
  16. Knapp BI
  17. Bidlack JM
  18. Zuiderveld OP
  19. Leurs R
  20. Ding X
  21. Hough LB
  Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling.; Nature neuroscience; Vol 13(3). 2010 Mar.
• 1. Fulton BS
  2. Knapp BL
  3. Bidlack JM
  4. Neumeyer JL
  Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 20(5). 2010 Mar 1.
• 1. Balboni G
  2. Salvadori S
  3. Trapella C
  4. Knapp BI
  5. Bidlack JM
  6. Lazarus LH
  7. Peng X
  8. Neumeyer JL
  Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.; ACS chemical neuroscience; Vol 1(2). 2010 Feb 17.
• 1. Decker M
  2. Si YG
  3. Knapp BI
  4. Bidlack JM
  5. Neumeyer JL
  Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.; Journal of medicinal chemistry; Vol 53(1). 2010 Jan 14.
• 1. Decker M
  2. Fulton BS
  3. Zhang B
  4. Knapp BI
  5. Bidlack JM
  6. Neumeyer JL
  Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.; Journal of medicinal chemistry; Vol 52(23). 2009 Dec 10.
• 1. Wentland MP
  2. Lou R
  3. Lu Q
  4. Bu Y
  5. Denhardt C
  6. Jin J
  7. Ganorkar R
  8. VanAlstine MA
  9. Guo C
  10. Cohen DJ
  11. Bidlack JM
  Syntheses of novel high affinity ligands for opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 19(8). 2009 Apr 15.
• 1. Wentland MP
  2. Lu Q
  3. Ganorkar R
  4. Zhang SZ
  5. Jo S
  6. Cohen DJ
  7. Bidlack JM
  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine.; Bioorganic & medicinal chemistry letters; Vol 19(2). 2009 Jan 15.
• 1. Wentland MP
  2. Lou R
  3. Lu Q
  4. Bu Y
  5. VanAlstine MA
  6. Cohen DJ
  7. Bidlack JM
  Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.; Bioorganic & medicinal chemistry letters; Vol 19(1). 2009 Jan 1.
• 1. Keyari CM
  2. Knapp BI
  3. Bidlack JM
  4. Lowey J
  5. Bilsky EJ
  6. Polt R
  Glycosyl-enkephalins: synthesis and binding at the mu, delta & kappa opioid receptors. Antinociception in mice.; Advances in experimental medicine and biology; Vol 611. 2009.
• 1. Bidlack JM
  2. Morris HH
  Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism.; Seizure; Vol 18(1). 2009 Jan.
• 1. Mathews JL
  2. Smrcka AV
  3. Bidlack JM
  A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence.; The Journal of neuroscience : the official journal of the Society for Neuroscience; Vol 28(47). 2008 Nov 19.
• 1. Mathews JL
  2. Fulton BS
  3. Negus SS
  4. Neumeyer JL
  5. Bidlack JM
  In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.; Neurochemical research; Vol 33(10). 2008 Oct.
• 1. Fulton BS
  2. Knapp BI
  3. Bidlack JM
  4. Neumeyer JL
  Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 18(16). 2008 Aug 15.
• 1. Wentland MP
  2. Sun X
  3. Cohen DJ
  4. Bidlack JM
  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine.; Bioorganic & medicinal chemistry; Vol 16(10). 2008 May 15.
• 1. Reed B
  2. Bidlack JM
  3. Chait BT
  4. Kreek MJ
  Extracellular biotransformation of beta-endorphin in rat striatum and cerebrospinal fluid.; Journal of neuroendocrinology; Vol 20(5). 2008 May.
• 1. VanAlstine MA
  2. Wentland MP
  3. Cohen DJ
  4. Bidlack JM
  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC.; Bioorganic & medicinal chemistry letters; Vol 17(23). 2007 Dec 1.
• 1. Peng X
  2. Knapp BI
  3. Bidlack JM
  4. Neumeyer JL
  In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.; Bioorganic & medicinal chemistry; Vol 15(12). 2007 Jun 15.
• 1. Zhang A
  2. Li F
  3. Ding C
  4. Yao Q
  5. Knapp BI
  6. Bidlack JM
  7. Neumeyer JL
  Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol.; Journal of medicinal chemistry; Vol 50(11). 2007 May 31.
• 1. Peng X
  2. Knapp BI
  3. Bidlack JM
  4. Neumeyer JL
  Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.; Journal of medicinal chemistry; Vol 50(9). 2007 May 3.
• 1. Peng X
  2. Knapp BI
  3. Bidlack JM
  4. Neumeyer JL
  High-affinity carbamate analogues of morphinan at opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 17(6). 2007 Mar 15.
• 1. Lowery JJ
  2. Yeomans L
  3. Keyari CM
  4. Davis P
  5. Porreca F
  6. Knapp BI
  7. Bidlack JM
  8. Bilsky EJ
  9. Polt R
  Glycosylation improves the central effects of DAMGO.; Chemical biology & drug design; Vol 69(1). 2007 Jan.